Heidelberg Pharma AG · XETR:HPHA
Heidelberg Pharma — Inv€$tival Showcase 2023
21 slides from Heidelberg Pharma's conference presentation, Nov 13, 2023
Slide 1: ATACs: Unique new mode of action to fight cancer
ATACs: Unique new mode of action to fight cancer Inv€$tival Showcase - 13th November 2023 © Heidelberg Pharma AG
Slide 2: Safe harbor
Safe harbor Forward looking statements This communication contains certain forward-looking statements, relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will” “should” “future”, “potential” or sim
Slide 3: Management team with strong pharma and R&D experience
Management team with strong pharma and R&D experience Dr. Jan Schmidt-Brand Dr. András Strassz CEO CMO Heidelberg Pharma since 2001 Heidelberg Pharma since 2020 30 years experience in commercial and financial leader- More than 15 years experience in clinical drug development including roles ship pos
Slide 4: Strong in-house R&D capabilities and expertise
Strong in-house R&D capabilities and expertise Synthetic chemistry Antibody generation Preclinical testing & bioconjugation CMC Bioanalytical sciences Clinical Development We are able to generate the best ADC candidate in the shortest time © Heidelberg Pharma AG 4
Slide 5: Key achievements
Key achievements Differentiated ADC Technology Strong IP • In Plug & Play mode • Several IP families • 2 years from target to IND • Monopoly in the Amanitin/MOA space GMP Manufacturing Strategic partnerships • Fully synthetic process • Huadong: China-focused partnership • 5 GMP batches completed • T
Slide 6: Value creation through development of best-in-class ADC assets
Value creation through development of best-in-class ADC assets Discovery & development engine Toolbox of proprietary Partnering at IND-ready, First payloads clinical data, EOP1, Clinical POC Multiple targets Scouting Partnering Co-Development In-licensing Upside : Retain territorial rights Developme
Slide 7: Resistance is one of the biggest challenges in oncology
Resistance is one of the biggest challenges in oncology 1 in 2 > 90% people will be diagnosed with cancer of cancer deaths are caused by in their lifetime drug resistance © Heidelberg Pharma AG 7
Slide 8: The journey of many cancer patients
The journey of many cancer patients Before Treatment Treatment Resistance & Relapse We need new drugs with new mode-of-action to overcome resistance © Heidelberg Pharma AG 8 Wagke, N.et al, J Clin Oncol. 2011; 29(22): 3085–3096
Slide 9: The Payload MOA is what makes the difference!
The Payload MOA is what makes the difference! 12-month PFS 75.8% Enhertu® Payload: deruxtecan (Topo 1 inhibitor) 34.1% Kadcyla® Payload: emtansine (Tubulin inhibitor) Source: Cortés, J. et al, N Engl J Med 2022; 386:1143-1154 Same target (Her2), same antibody (Trastuzumab), same patient population ©
Slide 10: Amanitin: Novel payload with novel MoA to overcome resistance
Amanitin: Novel payload with novel MoA to overcome resistance Tubulin inhibitors DNA-damaging agents Topoisomerase RNA polymerase e.g. Maytansines & e.g. PBDs, PDDs, IGNs, inhibitors inhibitors Auristatines Calicheamicin, e.g. Camptothecins, Duocarmycins Deruxtecan, SN-38 Amanitin Potency High Ultra
Slide 11: ATACs are ADCs with amanitin as a payload
ATACs are ADCs with amanitin as a payload Antibody • Targeting tumor antigen Amanitin as warhead • Differentiated mechanism of action: inhibition of RNA Polymerase II • Kills dormant tumor cells • Overcomes resistance • Predictive biomarker • Synthetic amanitin derivatives with improved properties •
Slide 12: ATACs overcome resistance to current ADCs
ATACs overcome resistance to current ADCs Breast cancer model (JIMT-1 Xenograft) is resistant to Kadcyla® and Enhertu® Trastuzumab ATAC leads to complete remission in resistant model after single-dose © Heidelberg Pharma AG 12
Slide 13: Growing pipeline of proprietary and partnered programs
Growing pipeline of proprietary and partnered programs Product Target Indication Research Preclinic Phase I Phase II Phase III Partner HDP-101 BCMA Multiple Myeloma Huadong (China+) ATAC pipeline HDP-102 CD37 NHL (DLBCL/CLL) Huadong (option China+) HDP-103 PSMA Prostate cancer Huadong (China+) HDP-1
Slide 14: First-in-human clinical trial with an ATAC ongoing
First-in-human clinical trial with an ATAC ongoing HDP-101: anti-BCMA-ATAC for multiple myeloma 2022/23 2024 2025 2026 Expansion Assess accelerated cohorts approval option Registrational Del(17p) stratified BLA cohort FPI Dose escalation in MM patients RP2D Non-stratified MM patients First clinical
Slide 15: ATACs promise significant clinical benefits
ATACs promise significant clinical benefits Unique preclinical features of ATACs Potential clinical benefit Efficacious against dormant tumor cells Longer PFS and MRD negativity Efficacious in ultra-low target-expressing tumor cells Deeper responses and higher ORR Novel MoA to which all patients wil
Slide 16: Partner Projects
Partner Projects © Heidelberg Pharma AG 16
Slide 17: Partner Projects
Partner Projects Strategic partnership with Huadong Medicine (February/September 2022) Exclusive licensing agreement for Asia* • Exclusive license for HDP-101 and HDP-103; deal value: up to USD 469 m + royalties • Exclusive option for HDP-102 and HDP-104; deal value: up to USD 461 m + royalties…
Slide 18: Highlights Legacy Portfolio: TELIX
Highlights Legacy Portfolio: TELIX TLX250-CDx is Progressing towards Market Approval TLX250-CDx (89Zr-girentuximab) (imaging) enables accurate diagnosis of clear cell renal cell carcinoma (ccRCC) Pivotal Phase III study (ZIRCON) reported positive results in November 2022 • Global multicenter phase I
Slide 19: Outlook
Outlook • We are a clinical-stage company with the goal of becoming a leading global ADC player • Multiple inflection points over the next 36 months with potential to many-fold increase of company valuation Q2/2026 Q2/2025 Q1/2025 Q3/2024 RP2D HDP-102 IND HDP-201 RP2D HDP-103 Q1/2024 IND HDP-103 RP2
Slide 20: Investment opportunity
Investment opportunity Solid cash runway until mid 2025 supports execution of ongoing programs and clinical validation of ATACs • Additional financing required to reach multiple value inflection points across our portfolio until end of 2026 • (Bridge-) Financing until non-dilutive funding becomes av
Slide 21: Heidelberg Pharma AG
Heidelberg Pharma AG Ladenburg, Germany Tel.: +49 6203 1009 0 investors@hdpharma.com www.heidelberg-pharma.com © Heidelberg Pharma AG 21